Drugs / Maxalt
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | RIZAFILM | — | 2026-02-26 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | MAXALT | — | 1999-11-16 – 2011-12-16 | fda.gov ↗ |
| Approved | US (FDA) | MAXALT-MLT | — | 1998-06-29 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00719134 | Sep 2008 → Dec 2013 | migraine disorder | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06473597 Comparator | Sep 2024 → Dec 2026 expected | migraine disorder | Antonios Likourezos | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-04-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Generic Maxalt® Tablets tevapharm.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Maxalt | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00719134 ↗ |
| Known as | Rizatriptan Benzoate | “Rizatriptan Benzoate (Maxalt MLT-ODT)” NCT06473597 ↗ |
| Action | Activate | “Rizatriptan benzoate (MAXALT), is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist.” NCT06473597 ↗ |
| Route | Oral | “Rizatriptan ODT 10mg orally disintegrating tablets” NCT06473597 ↗ |